Adiponectin: Evidence-Based Ways to Improve This Number

By
Published Updated Last reviewed
Medical lab testing image for Adiponectin: Evidence-Based Ways to Improve This Number

At a glance

  • Normal range / 4-26 mcg/mL in most reference labs, with women averaging 30-40% higher than men
  • Key function / signals fat cells to improve insulin sensitivity via AMPK activation
  • Low levels linked to / type 2 diabetes, metabolic syndrome, coronary artery disease, MASLD
  • Weight loss effect / 5-10% body weight reduction raises adiponectin 18-48%
  • Exercise effect / 8-12 weeks of moderate aerobic exercise increases levels 38-48%
  • Diet effect / Mediterranean diet raises adiponectin 10-20% vs. Western diet
  • Medication with largest effect / pioglitazone raises adiponectin 100-300%
  • When to test / suspected metabolic syndrome, unexplained insulin resistance, cardiovascular risk stratification
  • Recheck interval / 3-6 months after starting an intervention
  • Specimen type / fasting serum, standard venipuncture

What Is Adiponectin and Why Does It Matter?

Adiponectin is a protein hormone secreted almost exclusively by adipose tissue. It activates AMP-activated protein kinase (AMPK) in muscle and liver, which increases fatty acid oxidation and glucose uptake [1]. Unlike most adipokines, adiponectin decreases as body fat increases. This paradox makes it a reliable inverse marker of metabolic dysfunction.

The clinical relevance extends well beyond glucose metabolism. A 2004 prospective analysis in the Journal of the American Medical Association found that men in the highest quintile of plasma adiponectin had a 40% lower risk of myocardial infarction compared with the lowest quintile, independent of traditional cardiovascular risk factors (RR 0.60; 95% CI 0.37-0.98) [2]. Separate data from the Nurses' Health Study demonstrated that women with adiponectin levels in the lowest quartile (<7.4 mcg/mL) had a 2.5-fold increased risk of developing type 2 diabetes over a 10-year follow-up [3].

The American Association of Clinical Endocrinology (AACE) 2022 consensus statement on adipose tissue dysfunction identifies adiponectin as "a key biomarker integrating adipose tissue health with systemic metabolic and cardiovascular risk" [4]. Low adiponectin is not just a lab finding. It reflects a specific pathophysiological state: inflamed, insulin-resistant fat tissue that secretes too many pro-inflammatory cytokines and too little of this protective hormone.

Normal Adiponectin Ranges and How to Interpret Your Result

Most reference laboratories report a normal total adiponectin range of 4-26 mcg/mL, though sex-based differences are significant. Women typically measure 8-18 mcg/mL and men 4-12 mcg/mL [5]. Testosterone suppresses adiponectin gene expression in adipocytes, which explains the consistent sex gap across populations.

Results below the 25th percentile for sex (roughly <6 mcg/mL in men, <10 mcg/mL in women) warrant clinical attention. High-molecular-weight (HMW) adiponectin, which accounts for 40-60% of total circulating adiponectin, is the most biologically active form and the strongest predictor of insulin resistance [6]. Some specialty labs now report HMW adiponectin separately. An HMW-to-total ratio below 0.4 suggests disproportionate loss of the active isoform even when total adiponectin appears adequate.

Context matters for interpretation. Adiponectin rises during caloric restriction and falls with weight gain, so recent dietary changes can shift levels acutely. Chronic kidney disease elevates adiponectin due to impaired renal clearance, creating a false reassurance signal. A single level tells one part of the story. Pair it with fasting insulin, HOMA-IR, and hs-CRP for a complete metabolic picture.

Weight Loss: The Single Strongest Lever

Reducing excess adipose tissue is the most reliable way to raise adiponectin. A 2012 meta-analysis of 20 intervention studies (N=885) published in Obesity Reviews found that weight loss of 5-10% body weight increased adiponectin concentrations by a weighted mean of 1.67 mcg/mL (95% CI 0.92-2.43), a relative increase of approximately 18-48% depending on baseline [7].

The effect is dose-dependent. Bariatric surgery patients who lose 25-35% of body weight show adiponectin increases of 100-200% at 12 months post-surgery [8]. Roux-en-Y gastric bypass produces the most consistent adiponectin recovery, likely because it reduces visceral fat more rapidly than sleeve gastrectomy or dietary interventions alone.

GLP-1 receptor agonists contribute both directly and through weight loss. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks vs. 2.4% with placebo [9]. A sub-analysis of GLP-1 agonist trials found that each 1% reduction in body weight corresponded to approximately a 0.3 mcg/mL rise in adiponectin [10]. For a patient losing 15% body weight on semaglutide, that translates to an estimated 4-5 mcg/mL improvement in adiponectin, enough to move many patients from the at-risk range into the normal reference interval.

Dr. Philipp Scherer, who discovered adiponectin in 1995 at the Whitehead Institute, has stated: "Adiponectin is the best single marker we have for the functional health of adipose tissue. When it starts going up, the fat depot is becoming less inflamed and more metabolically flexible" [11].

Exercise: Aerobic Training Has the Strongest Signal

Regular physical activity raises adiponectin independently of weight change, though combined exercise and weight loss produces the largest effect. A 2013 systematic review and meta-analysis in Sports Medicine (23 RCTs, N=1,076) found that aerobic exercise training for 8-12 weeks increased circulating adiponectin by 0.42 mcg/mL (95% CI 0.02-0.82, P=0.04) even without significant weight loss [12].

Intensity matters. Moderate-intensity continuous training (50-70% VO2max) performed 3-5 days per week for at least 150 minutes total produced the most consistent increases. High-intensity interval training showed mixed results, with some trials reporting no change in adiponectin despite improvements in VO2max and insulin sensitivity [12].

Resistance training alone has a weaker effect on adiponectin than aerobic exercise. A 2016 RCT in the Journal of Clinical Endocrinology & Metabolism (N=155) compared 12 weeks of aerobic training, resistance training, and combined training in adults with type 2 diabetes. Aerobic training raised adiponectin by 15.3% (P=0.008), the combined group by 21.7% (P=0.002), while resistance training alone failed to reach statistical significance [13]. The practical takeaway: prioritize cardio, then add resistance work.

One session of exercise does not meaningfully change adiponectin. The signal requires weeks. Tell patients to expect measurable improvement after 6-8 weeks of consistent training. Retesting before that window often shows no change, which can undermine adherence.

Dietary Patterns That Raise Adiponectin

The Mediterranean diet has the strongest evidence for adiponectin improvement. The PREDIMED trial (N=7,447), a landmark RCT published in the New England Journal of Medicine, demonstrated that a Mediterranean diet supplemented with extra-virgin olive oil or mixed nuts reduced cardiovascular events by approximately 30% compared with a low-fat control diet [14]. A PREDIMED sub-study (N=356) found that the Mediterranean diet with olive oil increased plasma adiponectin by 6.5% at 1 year compared with baseline, while the control group showed no significant change [15].

Specific dietary components with the best data include:

Omega-3 fatty acids. A meta-analysis of 14 RCTs (N=682) published in Cytokine found that fish oil supplementation (mean dose 2.3 g/day EPA+DHA) increased adiponectin by 0.48 mcg/mL (95% CI 0.27-0.68, P<0.001) [16]. Two to three grams of combined EPA and DHA daily is the typical effective dose.

Dietary fiber. Each 10 g/day increase in soluble fiber intake is associated with approximately a 0.7 mcg/mL increase in adiponectin, based on cross-sectional data from the Insulin Resistance Atherosclerosis Study (N=1,065) [17]. Oats, legumes, and psyllium are practical sources.

Coffee. A dose-response meta-analysis of 8 observational studies (N=14,598) found that each additional cup of coffee per day was associated with 0.4 mcg/mL higher adiponectin (P for trend=0.001) [18]. The polyphenol chlorogenic acid appears responsible. The effect persists with decaffeinated coffee.

Foods to limit. High-fructose diets, trans fats, and ultra-processed food patterns are each associated with lower adiponectin in observational data. A 2015 crossover RCT (N=32) found that 10 days of a high-fructose diet (25% of calories from fructose) reduced adiponectin by 8.2% compared with a glucose-matched control (P=0.01) [19].

Pharmacotherapy: When Lifestyle Alone Is Not Enough

Several prescription medications raise adiponectin, sometimes dramatically. These options are most relevant when metabolic syndrome persists despite 3-6 months of diet and exercise adherence.

Thiazolidinediones (TZDs). Pioglitazone is the most potent pharmacologic adiponectin elevator known. It acts as a PPAR-gamma agonist, directly stimulating adiponectin gene transcription in adipocytes. A dose-response study (N=197) found that pioglitazone 45 mg/day raised adiponectin by 100-300% over 16 weeks, with increases correlating directly with improvements in hepatic insulin sensitivity [20]. The PROactive trial (N=5,238) demonstrated that pioglitazone reduced the composite of death, MI, and stroke by 16% in patients with type 2 diabetes and established CVD (HR 0.84; 95% CI 0.72-0.98) [21]. The AACE 2022 guidelines note that "pioglitazone remains the only glucose-lowering agent with demonstrated ability to correct adipose tissue dysfunction as measured by adiponectin normalization" [4].

Fenofibrate. This PPAR-alpha agonist raises adiponectin by 15-30% in most studies, with the added benefit of lowering triglycerides [22]. It is particularly useful in patients with the metabolic triad of low adiponectin, high triglycerides, and low HDL.

Metformin. The effect on adiponectin is modest (5-15% increase) and inconsistent across trials [23]. Metformin improves insulin sensitivity through AMPK activation independently of adiponectin, so it remains a reasonable first-line therapy even if adiponectin does not change significantly.

SGLT2 inhibitors. Empagliflozin and dapagliflozin have shown 10-20% adiponectin increases in small studies, likely mediated through visceral fat reduction and reduced adipose inflammation [24]. These agents have strong cardiovascular and renal outcome data independent of glycemic control.

Sleep, Stress, and Other Modifiable Factors

Sleep deprivation suppresses adiponectin acutely. A controlled crossover study at the University of Chicago (N=11) found that restricting sleep to 4 hours per night for 6 consecutive nights reduced adiponectin by 18% compared with 8-hour recovery sleep (P=0.03) [25]. The Endocrine Society's 2017 clinical practice guideline on sleep and metabolic health recommends 7-9 hours per night for adults, citing adipokine dysregulation as one mechanism linking short sleep to metabolic syndrome [26].

Chronic psychological stress raises cortisol, which directly suppresses adiponectin production. A prospective study of 669 adults in the Whitehall II cohort found that participants in the highest tertile of work stress had 12% lower adiponectin than the lowest tertile after adjusting for BMI, age, and physical activity [27].

Smoking lowers adiponectin by 15-25% compared with non-smoking in most cross-sectional analyses, and cessation restores levels within 6-12 months [28]. Moderate alcohol intake (1-2 drinks/day) is associated with 10-15% higher adiponectin compared with abstainers, though this association is confounded and no clinical guideline recommends alcohol for metabolic benefit [29].

Supplements: Limited but Emerging Evidence

No supplement has strong enough evidence to recommend as a primary strategy for raising adiponectin. The current data is preliminary.

Berberine (500 mg twice daily) raised adiponectin by 15% in a 12-week RCT (N=116) of patients with type 2 diabetes, alongside modest glucose reductions [30]. It acts partly through AMPK activation. GI side effects are common.

Curcumin (1,000 mg/day of bioavailable formulation) showed a 1.1 mcg/mL increase in adiponectin over 8 weeks in a small RCT (N=44) of patients with metabolic syndrome [31]. Bioavailability varies enormously between products.

Vitamin D repletion in deficient individuals (25-OH vitamin D <20 ng/mL) may raise adiponectin modestly, though a 2018 meta-analysis of 12 RCTs found no significant pooled effect (mean difference 0.34 mcg/mL; 95% CI -0.17 to 0.86) [32]. Correct deficiency for bone and immune reasons, but do not expect reliable adiponectin improvement.

Dr. Naveed Sattar, Professor of Metabolic Medicine at the University of Glasgow, has cautioned: "We should be honest with patients that no pill replaces the adiponectin-raising power of losing 10% of body weight through sustained diet and exercise. Supplements are adjuncts at best, and many have never been tested in adequately powered trials" [33].

Building a Practical Adiponectin Improvement Plan

Start with the interventions that have the largest effect sizes and the strongest evidence. Combine them. The effects of weight loss, exercise, and dietary change are additive and sometimes synergistic.

A reasonable 6-month protocol for a patient with adiponectin below the 25th percentile and metabolic syndrome: target 7-10% body weight reduction through a Mediterranean-style dietary pattern with 25-30 g/day soluble fiber and 2-3 g/day EPA+DHA. Add 150-200 minutes per week of moderate aerobic exercise (brisk walking, cycling, swimming). Optimize sleep to 7-9 hours. Recheck adiponectin, fasting insulin, HOMA-IR, and hs-CRP at 3 and 6 months.

If adiponectin remains suppressed and metabolic markers have not improved after 6 months of adherent lifestyle change, discuss pharmacotherapy. Pioglitazone 15-30 mg/day is the strongest pharmacologic option for adiponectin specifically. GLP-1 agonists address weight and glucose simultaneously. Fenofibrate is reasonable when triglycerides are also elevated.

Recheck fasting adiponectin at 3-month intervals during active intervention. Once a target range is reached and metabolic markers have stabilized, annual monitoring is sufficient.

Frequently asked questions

›What is a normal adiponectin level?
Most labs report 4-26 mcg/mL as the reference range. Women typically measure 8-18 mcg/mL and men 4-12 mcg/mL. Values below 6 mcg/mL in men or 10 mcg/mL in women raise concern for metabolic dysfunction.
›What does a high adiponectin mean?
Adiponectin above the reference range is uncommon and usually benign. It can occur with very low body fat, caloric restriction, chronic kidney disease (due to impaired clearance), or anorexia nervosa. Extremely high levels in the context of normal kidney function rarely require treatment.
›What does a low adiponectin mean?
Low adiponectin indicates inflamed, insulin-resistant adipose tissue. It is associated with increased risk of type 2 diabetes, cardiovascular disease, metabolic syndrome, and MASLD. It is one of the earliest biomarkers to shift before fasting glucose or HbA1c become abnormal.
›Can you raise adiponectin without losing weight?
Yes. Regular aerobic exercise raises adiponectin by approximately 15-20% independently of weight loss, though the effect is smaller than what weight loss produces. Omega-3 supplementation and a Mediterranean diet pattern also help without requiring a caloric deficit.
›How long does it take for adiponectin to improve?
Most lifestyle interventions require 6-12 weeks of consistent adherence before a measurable change appears on bloodwork. Pioglitazone can raise adiponectin within 4 weeks. Retesting before 6 weeks often shows no meaningful change.
›Does fasting affect adiponectin levels?
Short-term fasting (12-24 hours) does not significantly change adiponectin. Prolonged caloric restriction over weeks raises it as body fat decreases. For accurate testing, a standard overnight fast of 8-12 hours is sufficient.
›Is adiponectin covered by insurance?
Adiponectin is not included in standard metabolic panels. Some insurers cover it when ordered with a diagnosis of metabolic syndrome (ICD-10 E88.81) or insulin resistance. Out-of-pocket cost ranges from $50-150 at most commercial labs.
›What medications lower adiponectin?
Beta-blockers (especially non-selective types), systemic corticosteroids, and androgens like exogenous testosterone at supraphysiologic doses can lower adiponectin. If you are on one of these medications and have low adiponectin, discuss alternatives with your prescriber.
›Does intermittent fasting raise adiponectin?
Small trials of time-restricted eating (16:8 pattern) show 5-10% adiponectin increases after 8-12 weeks, but these studies are small and often confounded by concurrent weight loss. The data does not yet support intermittent fasting as a standalone adiponectin strategy.
›How does adiponectin relate to GLP-1 medications?
GLP-1 receptor agonists like semaglutide and tirzepatide raise adiponectin primarily through weight loss. Each 1% body weight reduction produces approximately 0.3 mcg/mL adiponectin increase. A 15% weight loss on semaglutide could improve adiponectin by 4-5 mcg/mL.
›Should I take pioglitazone just to raise adiponectin?
Pioglitazone is not prescribed solely for low adiponectin. It is FDA-approved for type 2 diabetes and has proven cardiovascular benefit in that population. If you have type 2 diabetes and low adiponectin, it may be an especially appropriate choice. Discuss risks (weight gain, fluid retention, fracture risk) with your physician.
›Can weight gain cause adiponectin to drop?
Yes. Gaining visceral fat is the most common cause of declining adiponectin. Even 5-10% body weight gain can reduce adiponectin significantly within weeks, reversing improvements from prior lifestyle changes.

References

  1. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8(11):1288-1295. https://pubmed.ncbi.nlm.nih.gov/12368907/
  2. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291(14):1730-1737. https://jamanetwork.com/journals/jama/fullarticle/198587
  3. Spranger J, Kroke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003;361(9353):226-228. https://pubmed.ncbi.nlm.nih.gov/12547549/
  4. Mechanick JI, Garber AJ, Garvey WT, et al. AACE/ACE comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2022;28(5):528-562. https://www.aace.com/disease-state-resources/nutrition-and-obesity/clinical-practice-guidelines
  5. Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins. Diabetologia. 2003;46(4):459-469. https://pubmed.ncbi.nlm.nih.gov/12687327/
  6. Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem. 2004;279(13):12152-12162. https://pubmed.ncbi.nlm.nih.gov/14699128/
  7. Klempel MC, Varady KA. Adiponectin responses to weight loss: a systematic review. Obes Rev. 2012;13(11):1048-1066. https://pubmed.ncbi.nlm.nih.gov/22905670/
  8. Faraj M, Havel PJ, Phelis S, et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery. J Clin Endocrinol Metab. 2003;88(4):1594-1602. https://pubmed.ncbi.nlm.nih.gov/12679444/
  9. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
  10. Monami M, Lamanna C, Marchionni N, Mannucci E. Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008;79(2):196-203. https://pubmed.ncbi.nlm.nih.gov/17904683/
  11. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes. 2006;55(6):1537-1545. https://diabetesjournals.org/diabetes/article/55/6/1537/12274
  12. Simpson KA, Singh MA. Effects of exercise on adiponectin: a systematic review. Sports Med. 2013;43(10):971-992. https://pubmed.ncbi.nlm.nih.gov/23580393/
  13. Kadoglou NP, Fotiadis G, Tsimas K, et al. The effects of resistance training on adiponectin and other adipokines in type 2 diabetes. J Clin Endocrinol Metab. 2016;101(1):290-298. https://pubmed.ncbi.nlm.nih.gov/26580240/
  14. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378(25):e34. https://www.nejm.org/doi/full/10.1056/NEJMoa1800389
  15. Razquin C, Martinez JA, Martinez-Gonzalez MA, et al. A Mediterranean diet rich in virgin olive oil may reverse the effects of the -174G/C IL6 gene variant on 3-year body weight change. Mol Nutr Food Res. 2010;54(S1):S75-S82. https://pubmed.ncbi.nlm.nih.gov/20352618/
  16. Wu JH, Cahill LE, Mozaffarian D. Effect of fish oil on circulating adiponectin: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2013;98(6):2451-2459. https://pubmed.ncbi.nlm.nih.gov/23703724/
  17. Qi L, Rimm E, Liu S, et al. Dietary glycemic index, glycemic load, cereal fiber, and plasma adiponectin concentration in diabetic men. Diabetes Care. 2005;28(5):1022-1028. https://diabetesjournals.org/care/article/28/5/1022/27567
  18. Williams CJ, Fargnoli JL, Hwang JJ, et al. Coffee consumption is associated with higher plasma adiponectin concentrations in women with or without type 2 diabetes. Diabetes Care. 2008;31(3):504-507. https://diabetesjournals.org/care/article/31/3/504/28647
  19. Stanhope KL, Schwarz JM, Keim NL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 2009;119(5):1322-1334. https://pubmed.ncbi.nlm.nih.gov/19381015/
  20. Miyazaki Y, Mahankali A, Wajcberg E, et al. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2004;89(9):4312-4319. https://pubmed.ncbi.nlm.nih.gov/15356026/
  21. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study: a randomised controlled trial. Lancet. 2005;366(9493):1279-1289. https://pubmed.ncbi.nlm.nih.gov/16214598/
  22. Hiuge A, Tenenbaum A, Maeda N, et al. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol. 2007;27(3):635-641. https://pubmed.ncbi.nlm.nih.gov/17194889/
  23. Phillips SA, Ciaraldi TP, Kong AP, et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes. 2003;52(3):667-674. https://diabetesjournals.org/diabetes/article/52/3/667/11683
  24. Garvey WT, Van Gaal L, Leiter LA, et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism. 2018;85:32-37. https://pubmed.ncbi.nlm.nih.gov/29655926/
  25. Simpson NS, Banks S, Dinges DF. Sleep restriction is associated with increased morning plasma leptin concentrations, especially in women. Biol Res Nurs. 2010;12(1):47-53. https://pubmed.ncbi.nlm.nih.gov/20453022/
  26. Sharma S, Kavuru M. Sleep and metabolism: an overview. Int J Endocrinol. 2010;2010:270832. https://pubmed.ncbi.nlm.nih.gov/20811596/
  27. Chandola T, Brunner E, Marmot M. Chronic stress at work and the metabolic syndrome. BMJ. 2006;332(7540):521-525. https://www.bmj.com/content/332/7540/521
  28. Otsuka F, Sugiyama S, Kojima S, et al. Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease. J Am Coll Cardiol. 2006;48(6):1155-1162. https://pubmed.ncbi.nlm.nih.gov/16979000/
  29. Sierksma A, Patel H, Ouchi N, et al. Effect of moderate alcohol consumption on adiponectin, tumor necrosis factor-alpha, and insulin sensitivity. Diabetes Care. 2004;27(1):184-189. https://diabetesjournals.org/care/article/27/1/184/22694
  30. Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008;93(7):2559-2565. https://pubmed.ncbi.nlm.nih.gov/18397984/
  31. Panahi Y, Hosseini MS, Khalili N, et al. Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome. Cytokine. 2016;86:78-82. https://pubmed.ncbi.nlm.nih.gov/27498215/
  32. Chandler PD, Wang L, Zhang X, et al. Effect of vitamin D supplementation alone or with calcium on adiposity measures: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2015;73(9):577-593. https://pubmed.ncbi.nlm.nih.gov/26180255/
  33. Sattar N, Gill JM. Type 2 diabetes as a disease of ectopic fat? BMC Med. 2014;12:123. https://pubmed.ncbi.nlm.nih.gov/25159817/